CAMP4 Therapeutics Reports Q1 2026 Financial Results with Increased Revenue and Net Loss

CAMP4 Therapeutics Corporation reported its financial results for the first quarter of 2026, revealing a research and collaboration revenue of $1.3 million, an increase from $858,000 in the same period last year. The company’s total operating expenses rose to $14.4 million, compared to $14.0 million in the first quarter of 2025, primarily driven by higher general and administrative costs. The net loss for the quarter was $18.3 million, a significant increase from the $12.4 million loss reported in the prior year, resulting in a net loss per share of $0.32, compared to $0.62 in the same quarter of 2025.

The company experienced a notable increase in its accumulated deficit, which reached $310.5 million as of March 31, 2026, up from $292.2 million at the end of 2025. This increase reflects ongoing investments in research and development, particularly in advancing its lead product candidate, CMP-002, which targets SYNGAP1-related disorders. The company’s cash and cash equivalents stood at $99.2 million, down from $109.5 million at the end of 2025, indicating a continued cash burn as it progresses through clinical trials and operational activities.

CAMP4 Therapeutics has made strategic advancements, including the initiation of a global Phase 1/2 clinical trial for CMP-002, pending regulatory approval. The company has also entered into significant collaboration agreements, including a recent partnership with GlaxoSmithKline, which contributed to the revenue recognized during the quarter. The company’s employee headcount has increased, reflecting its efforts to bolster its research and development capabilities in anticipation of upcoming clinical trials.

Operationally, the company reported a slight increase in research and development expenses, totaling $10.2 million for the quarter, driven by higher personnel-related costs and clinical expenses. General and administrative expenses also rose to $4.2 million, attributed to increased stock-based compensation and professional fees. The company’s cash flow from operating activities showed improvement, with a net cash usage of $11.0 million compared to $14.3 million in the same quarter of the previous year, indicating a potential stabilization in cash burn rates.

Looking ahead, CAMP4 Therapeutics anticipates continued investment in its product development pipeline and expects to incur significant expenses as it seeks regulatory approvals and prepares for potential commercialization of its product candidates. The company has indicated that its current cash reserves are expected to fund operations into 2028, although it remains dependent on future capital raises to support ongoing and future initiatives.